INDOCIN (indomethacin) by R-Pharm US is cyclooxygenase inhibitors [moa]. First approved in 1985.
Drug data last refreshed 7h ago · AI intelligence enriched 5d ago
INDOCIN (indomethacin) is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain. It is available as an oral suspension and has been used clinically since 1985 for various inflammatory and pain conditions. The drug addresses unmet needs in patients requiring oral anti-inflammatory therapy.
As LOE approaches, the brand team will shift focus to lifecycle extension, line extension through formulation innovation, and defending market share against generic erosion.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Worked on INDOCIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on INDOCIN offers exposure to mature product management, competitive repositioning, and navigating LOE challenges—valuable skills for any pharma professional. This role emphasizes strategic thinking around generic competition, market defense, and potential line extensions rather than primary launch activities.